ROS activated prodrug for ALDH overexpressed cancer stem cells

Miae Won, Ji Hyeon Kim, Myung Sun Ji, Jong Seung Kim

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Aldehyde dehydrogenase (ALDH), a cancer stem cell biomarker, is related to drug resistance. Co-treatment of anti-cancer drug (CPT) and ALDH inhibitor (DEAB) can overcome the drug resistance of cancer stem cells (CSCs) and finally cure cancers without relapse. We herein introduce a prodrug (DE-CPT) - consisting of 1,3-oxathiolane as an ROS responsive scaffold, and an aldehyde protecting group of DEAB - to deliver the CPT and DEAB upon reaction with ROS. From tests of the sphere-forming ability and CSC marker subpopulation, we found that DE-CPT efficiently decreases the CSCs population and kills the cancer cells.

Original languageEnglish
Pages (from-to)72-75
Number of pages4
JournalChemical Communications
Issue number1
Publication statusPublished - 2022 Jan 4

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (CRI project no. 2018R1A3B1052702 and no. 2019M3E5D1A01068998, J. S. K.) and the global PhD fellowship (GPF) program (no. 2019H1A2A1074096, J. H. K.), funded by the Ministry of Education. This research was supported by the Korea University Graduate School Junior Fellow Research Grant (J. H. K).

Publisher Copyright:
© The Royal Society of Chemistry 2021.

ASJC Scopus subject areas

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • General Chemistry
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry


Dive into the research topics of 'ROS activated prodrug for ALDH overexpressed cancer stem cells'. Together they form a unique fingerprint.

Cite this